Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer (CheckVAC)

2024-515966-14-00 Protocol PA 2217 Human pharmacology (Phase I) - First administration to humans Ended

Start 3 May 2023 · End 16 Mar 2026 · Status Ended · 1 EU/EEA countries · 1 sites · Protocol PA 2217

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - First administration to humans
Status Ended
Participants planned 20
Countries 1
Sites 1

advanced pancreatic cancer

Key facts

Sponsor
Region Hovedstaden
Participant type
Patients
Age range
18-64 years, 65+ years
Gender
Male and Female
Therapeutic area
Diseases [C] - Neoplasms [C04]
Trial duration
3 May 2023 → 16 Mar 2026
Decision date (initial)
2024-09-13
Transition trial
Yes
Low-intervention
No
Rare-disease indication
No
Vulnerable population
Yes

External identifiers

EU CT number
2024-515966-14-00
EudraCT number
2022-002734-13
ClinicalTrials.gov
NCT05721846

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

advanced pancreatic cancer

VersionLevelCodeTermSystem organ class
27.0 LLT 10033605 Pancreatic cancer metastatic 10029104
21.0 LLT 10033607 Pancreatic cancer recurrent 10029104
21.0 LLT 10033606 Pancreatic cancer non-resectable 10029104

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Region Hovedstaden

Sponsor organisation
Region Hovedstaden
Address
Borgmester Ib Juuls Vej 1
City
Herlev
Postcode
2730
Country
Denmark

Scientific contact point

Organisation
Region Hovedstaden
Contact name
Sponsor Investigator Inna Chen

Public contact point

Organisation
Region Hovedstaden
Contact name
Sponsor Investigator Inna Chen

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Denmark Ended 20 1
Rest of world 0

Investigational sites

Denmark

1 site · Ended
Region Hovedstaden
Department of Oncology, Borgmester Ib Juuls Vej 1, 2730, Herlev

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Denmark 2023-05-03 2026-03-16 2023-05-16 2025-03-27

Application history

2 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2024-09-03 Denmark Acceptable
2024-09-13
2024-09-13
2 SUBSTANTIAL MODIFICATION SM-1 2025-10-21 Denmark Acceptable
2025-11-26
2025-11-26